Skip Navigation

European Heart Journal 1993 14(Supplement H):62-66; doi:10.1093/eurheartj/14.suppl_H.62
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Edvardsson, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edvardsson, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

Comparison of class I and class III action in atrial fibrillation

N. Edvardsson

Sahlgren's Hospital Göteborg, Swden

Correspondence: Nils Edvardsson, MD, Division of Cardiology, Sahlgren's Hospital, S-41345 Göteborg, Sweden

Antiarrhythmic agents with class I action have been available for decades, and those with class III mode of action for mon than 10 years. However, no randomized, controlled, direct comparison between agents with class I and class III mode of action was performed until recently. In patients with successful DC conversion of chronic atrial fibrillation, sotalol proved to be as effective as quinidine in maintaining sinus rhythm but was better tolerated and provided beneficial rate control during atrial fibrillation in those patients who relapsed. In other clinical settings, such as the pharmacological conversion os acute or paroxysmal atrial fibrillation and the termination of and/or prophylaxis against atrial fibrillation after coronary artery bypass surgery, less reliable data is available. Both commonly-available agents with a class III mode of action, amiodarone and sotalol, also have other significant antiarrhythmic properties; for sotalol, the combination of class III activity ana beta blockade may prove to be favourable. Therefore, the available data is not necessarily representative of a pure class III mode of action. Ongoing studies with d-sotalol in patients with atrial fibrillation will provide the first important information on the clinical usefulness of a class III mode of action without subsidiary effects. Whether d-sotalol or other new class III agents will, in the future, be compared to class I agents still remains an open question.

Key Words: Atrial fibrillation • antiarrhythmic agents • amiodarone • sotalol


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
C. Katsenis, E. Kouskouni, L. Kolokotronis, D. Rizos, and P. Dimakakos
The Significance of Chlamydia pneumoniae in Symptomatic Carotid Stenosis
Angiology, September 1, 2001; 52(9): 615 - 619.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.